ROCKET PHARMACEUTICALS INC (RCKT) Stock Price, Quote, News and Overview
NASDAQ:RCKT - Nasdaq - US77313F1066 - Common Stock - Currency: USD
RCKT Quote, Performance and Key Statistics
10.47
-0.4 (-3.68%)
The current stock price of RCKT is 10.47 USD. In the past month the price decreased by -5.51%. In the past year, price decreased by -64.24%.
RCKT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About RCKT
Company Profile
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 268 full-time employees. The company went IPO on 2015-02-18. The firm is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. The company also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.
Company Info
ROCKET PHARMACEUTICALS INC
9 Cedarbrook Drive
Cranbury NEW JERSEY 08512 US
CEO: Gaurav Shah
Employees: 268
Company Website: https://www.rocketpharma.com/
Investor Relations: https://rocketpharmaceuticals.gcs-web.com/
Phone: 16464409100
ROCKET PHARMACEUTICALS INC / RCKT FAQ
What is the stock price of ROCKET PHARMACEUTICALS INC today?
The current stock price of RCKT is 10.47 USD. The price decreased by -3.68% in the last trading session.
What is the ticker symbol for ROCKET PHARMACEUTICALS INC stock?
The exchange symbol of ROCKET PHARMACEUTICALS INC is RCKT and it is listed on the Nasdaq exchange.
On which exchange is RCKT stock listed?
RCKT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ROCKET PHARMACEUTICALS INC stock?
23 analysts have analysed RCKT and the average price target is 43.57 USD. This implies a price increase of 316.13% is expected in the next year compared to the current price of 10.47. Check the ROCKET PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ROCKET PHARMACEUTICALS INC worth?
ROCKET PHARMACEUTICALS INC (RCKT) has a market capitalization of 1.11B USD. This makes RCKT a Small Cap stock.
How many employees does ROCKET PHARMACEUTICALS INC have?
ROCKET PHARMACEUTICALS INC (RCKT) currently has 268 employees.
What are the support and resistance levels for ROCKET PHARMACEUTICALS INC (RCKT) stock?
ROCKET PHARMACEUTICALS INC (RCKT) has a resistance level at 11.25. Check the full technical report for a detailed analysis of RCKT support and resistance levels.
Should I buy ROCKET PHARMACEUTICALS INC (RCKT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RCKT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RCKT, evaluating the profitability, health, valuation and growth aspects
- ROCKET PHARMACEUTICALS INC (RCKT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ROCKET PHARMACEUTICALS INC (RCKT) Sales and EPS estimates to see what analysts future expectations are.
- ROCKET PHARMACEUTICALS INC (RCKT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ROCKET PHARMACEUTICALS INC (RCKT) Insider and Institutional Ownership to learn about the owners and their transactions.
- ROCKET PHARMACEUTICALS INC (RCKT) Stock Chart to make your own analysis
- ROCKET PHARMACEUTICALS INC (RCKT) Latest news and press-releases to stay up to date.
Does ROCKET PHARMACEUTICALS INC (RCKT) stock pay dividends?
RCKT does not pay a dividend.
When does ROCKET PHARMACEUTICALS INC (RCKT) report earnings?
ROCKET PHARMACEUTICALS INC (RCKT) will report earnings on 2025-03-06, after the market close.
What is the Price/Earnings (PE) ratio of ROCKET PHARMACEUTICALS INC (RCKT)?
ROCKET PHARMACEUTICALS INC (RCKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.75).
What is the Short Interest ratio of ROCKET PHARMACEUTICALS INC (RCKT) stock?
The outstanding short interest for ROCKET PHARMACEUTICALS INC (RCKT) is 10.45% of its float. Check the ownership tab for more information on the RCKT short interest.
RCKT Technical Analysis
RCKT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RCKT. RCKT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RCKT Financial Highlights
Over the last trailing twelve months RCKT reported a non-GAAP Earnings per Share(EPS) of -2.75. The EPS increased by 14.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.55% | ||
| ROE | -78.26% | ||
| Debt/Equity | 0.06 |
RCKT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to RCKT. The Buy consensus is the average rating of analysts ratings from 23 analysts.